WSJ
04 Nov 2026, 11:42 UTC · 31m ago
CVS Raises Forecast on Health Care Benefits, Pharmacy Gains
Impact · against what's priced in
The guidance raise is not a catalyst for CVS as the market has already priced in the updated 2026 EPS and cash flow targets. The company's continued caution regarding costs reinforces the current valuation's refusal to credit sustained margin expansion.
- CVS+0.00
Already priced in
- The price assumes
The raised full-year adjusted EPS guidance of $7.90–$8.10 and the upgraded operating cash flow forecast of at least $11.5 billion.
The price already accounts for the raised full-year guidance and the gains in health-care benefits and pharmacy segments. The stated caution regarding high costs aligns with why the market is currently discounting the stock at the bottom of analyst targets.
What CVS's price assumes · Sep 9
Top 1 mover · tap to explore
